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ABSTRACT
O bjective : Control of hypertension (HT) can lead 
to regression of left ventricular mass index 
(LVMI) especially in the first year of renal 
transplantation. However, effect of better control 
of blood pressure (BP) on regression of LVMI in 
long-term renal transplant recipients is not 
known. In this study, we aimed to determine 
whether improved control of HT would decrease 
LVMI in renal transplant recipients or not.
M ethods: Twenty-four nondiabetic renal
transplant recipients were included in the final 
analysis. Patients were categorized into group A 
(controlled-HT) and group B (uncontrolled-HT) 
according to their daytime blood pressure levels 
at the beginning of the study. Antihypertensive 
drug treatment of patients in group B was 
modified according to ambulatory blood pressure 
monitorization (ABPM) and clinical 
measurements. Echocardiographic examination 
was performed at baseline and at the end of 24 
month.
R e su lts : Systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) declined 
significantly (p<0.01) in parallel to increased use 
of angiotensin converting enzyme inhibitor 
(p<0.01) and LVMI remained unchanged in 
group B (113 ± 34 g / m2 vs 112 ± 29 g / m2 at 
baseline and at the end of 24 month,
respectively). Although SBP and DBP did not 
change significantly in group A, LVMI increased 
significantly (90 ±21 g / m2 to 107 ± 26 g / m2 at 
baseline and at the end of 24 month, 
respectively) in parallel to increase in serum 
creatinine (p<0.05) and decline in hemoglobin 
levels.
C o n c lu s io n s : Our results suggest that control of 
BP is not sufficient either for the regression or 
maintenance of LVMI in long term renal 
transplant recipients. However, factors such as 
low hemoglobin level and worsening of renal 
function may play critical roles in the progression 
of LVMI even in patients with well-controlled BP.
K e y  W o rd s : Renal transplantation, Left 
ventricular hypertrophy, Hypertension, 
Ambulatory blood pressure monitoring
INTRODUCTION
Cardiovascular disease is the most common 
cause of death after renal transplantation (1, 2). 
Left ventricular hypertrophy (LVH) is an 
independent predictor of mortality in patients with 
end-stage renal disease (3). The presence of 
increased left ventricular mass index (LVMI) in 
the pretransplant period may also be responsible 
for the premature death after renal
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transplantation (4). Moreover, increased LVMI in 
the early posttransplant period was related to 
increased mortality rate after transplantation (5). 
Hypertension has a major influence in the 
development of LVH. Additional factors, such as 
uremia, hyperparathyroidism, volume overload, 
high cardiac output state due to anemia, and 
arteriovenous fistula are also operative in the 
development of LVH in patients undergoing 
hemodialysis (6). Although, reduction of LVH has 
not been a consistent observation (7), it is mostly 
reported that correction of uremia-related factors 
and hypertension lead to regression of LVM and 
normalization of cardiac function, principally 
during the first year after renal transplantation (8-
10). The persistence of hypertension was 
reported as the most important factor responsible 
for the failure of further regression of LVMI 
beyond the second year after renal 
transplantation (10).
Studies, aimed to investigate the effect of blood 
pressure (BP) control on the regression of LVMI, 
were either conducted in the early post­
transplant period or study population consisted of 
the patients with uncontrolled BP (9). There is no 
prospective report that specifically addressed the 
effect of better control of HT on LVMI after the 
first year in renal transplant recipients.
In this study, we aimed to determine whether the 
improvement in HT control by means of stepped 
approach with antihypertensive therapy will 
improve left ventricular structure in renal 
transplant recipients one year after renal 
transplantation.
MATERIALS AND METHODS
Study population
Forty-three nondiabetic renal transplant 
recipients who were followed up at the renal 
transplant clinic of Marmara University Hospital 
were candidates for the study. The local ethics 
committee approved the study protocol and all 
patients gave written informed consent prior to 
inclusion to the study. All of the patients 
underwent echocardiography and ABPM 
measurement at baseline and at the end of study 
period. Renal transplant recipients with duration 
of renal transplantation less than 12 months (n =
5), functional arteriovenous fistula (n = 1), serum
creatinine level above 2.0 mg / dl (n = 5), more 
than 20 % increase in serum creatinine at any 
time during the preceding 12 months (n = 2) and 
severe valvular heart disease (n = 1) were 
excluded from the study. The remaining 29 renal 
transplant recipients (aged 35 ± 9 years, mean 
duration of transplantation of 49 ± 32 months) 
were included in the the study irrespective of 
their BP levels and LVMI. The duration of renal 
transplantation was between 13 to 24 months in 
10 recipients, between 25 to 36 months in 6, 
between 37 to 48 months in 3, between 49 to 60 
months in 2 and more than 61 months in 8 
recipients. The causes of pretransplant renal 
failure were chronic glomerulonephritis (34 %), 
hypertensive nephrosclerosis (28 %), chronic 
pyelonephritis (21 %), and unknown etiology (13 
%). Five renal transplant recipients (3 male and 2 
female; aged 37 ± 5 years) who had their serum 
creatinine increased more than 20 % during 
study period compared to baseline (n = 3), or 
whose echocardiography was unavailable (n = 2) 
were excluded from the final analysis at the end 
of 24 months of follow up.
All renal transplant recipients were on triple 
immunosuppressive treatment consisting of 
cyclosporine, prednisolone and azathioprine. 
The serum level of cyclosporine was between 
100 and 200 ng / ml. The dose of prednisolone 
and azathiprine were 5 to 10 mg / day and 1 mg 
/ kg / day, respectively.
Blood P re ssu re  M easurem ents
Twenty-four hours ambulatory blood pressure 
monitoring (ABPM) was performed according to 
the method described previously (11) at baseline 
and 24 months after the last modification of 
antihypertensive drugs. ABPM device (Spacelab 
90207; Spacelabs Inc., Redmond, WA, USA) was 
programmed for 24 hours with readings for every 
20 minutes from 07.00 to 23.00 and every 30 
minutes from 23.00 to 07.00. Monitors were 
calibrated against a mercury sphygmomanometer 
at the beginning of each session. According to the 
baseline recordings, patients were categorized as 
“controlled HT” (n = 14) with daytime ABPM 
below 135/85 mm Hg or “uncontrolled HT" (n = 
10) with mean daytime ABPM > 135/85 mm Hg 
according to current definitions and criteria used 
by Burt and colleagues (12,13). Renal transplant 
recipients with "controlled-HT" constituted group 
A, and patients with "uncontrolled-HT" constituted
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group B. Antihypertensive medications were 
modified according to ABPM measurements at 
baseline and further revised by ABPM 
measurements or clinical BP measurements at 
regular intervals during outpatient visits according 
to recent guidelines (12). Clinical BP was 
measured from the same upper extremity using a 
mercury sphygmomanometer with the patient in a 
sitting position. After 10 minutes of rest, the 
averages of three consecutive measurements 
performed 5 minutes apart were accepted as the 
final BP value.
Ech o card io g rap h ic  a sse ssm e n t
Two-dimensional guided M-mode
echocardiography was performed by standard 
methods using an ultrasound system (Ultramark 
9, Advanced Technology Laboratories, Bothell, 
WA, USA) with a 2.25-MHz transducer. Left 
ventricular internal dimension (LVID), 
interventricular septal thickness (IVST) and 
posterior wall thickness (PWT) were measured at 
end-diastole according to the American Society 
of Echocardiography recommendations (14). Left 
ventricular mass (LVM) was calculated using the 
thick-wall prolate-ellipsoidal model with 
correction based on a necropsy validation study 
by Devereux et al. (15): 0.832 X [(LVID + IVST + 
PWT)3 - LVID3] + 0.6. LVM was considered as an 
unadjusted variable and normalized for body 
surface area (BSA) as left ventricular mass index 
(LVMI). BSA was calculated by using the Du Bois 
formula: 0.007184 X (weight [kg])0-425 X (height 
[cm])0-725.
Laboratory m easurem ents
Serum creatinine was measured using a 
computerized auto—analyzer (Hitachi 717, 
Boehringer Mannheim, Germany). Blood 
cyclosporine-A level was analyzed by FPIA 
assay using a monoclonal antibody (Abbott, IL, 
USA).
S ta tistica l a n a ly s is
All calculations were done using SPSS computer 
program. Data were expressed as mean ± SD. 
Comparisons between groups A and B were 
performed by using Mann Whitney U test. 
Comparisons within the groups were done using 
Wilcoxon signed rank test. Fischer’s exact test 
was used for the analysis of categorical 
variables. A two-tailed p value less than 0.05 
were considered significant.
RESULTS
The clinical characteristics and laboratory data 
of group-A (controlled HT) and group B 
(uncontrolled-HT) are presented in Table I. 
There were no significant differences in serum 
creatinine, hemoglobin, cyclosporine level, the 
duration of dialysis previous to transplantation 
and the duration of renal transplantation 
between the two groups at baseline. Serum 
creatinine level increased mildly but significantly 
in group A at the end of 24th month of follow-up 
(p<0.05).
ABPM data are presented in Table II. Daytime, 
nighttime and 24-h ABPM measurements were 
significantly higher in group B compared to group 
A at baseline. 24-h SBP decreased from 143 ± 
12 mm Hg to 126 ± 8 mm Hg (p < 0.01) and 24- 
h DBP decreased from 88 ± 6 mm Hg to 77 ± 7 
mm Hg (p < 0.01) in group B at the end of follow­
up period (Table II). However, 24-SBP and 
daytime SBP values were still higher in group-B 
compared to respective values in group A at 24th 
month. Finally, only 3 patients (30%) had 
uncontrolled HT according to daytime ABPM 
values (135/87 mm Hg, 137/77 mm Hg and 
135/93 mm Hg, respectively) after 24 months in 
group B. All of the patients in group A had 
controlled BP at the end of study period. Number 
of antihypertensives prescribed in group B 
increased significantly from 1.5 ± 0.5 at baseline 
to 2.6 ± 0.5 after 24 months (p < 0.01), whereas 
the number of antihypertensives did not change 
in group A. The number of patients receiving 
angiotensin converting enzyme inhibitors (ACEI) 
were significantly higher in group B than in group 
A at the end of study period (29% vs. 80%, 
p<0.05) (Table I). There was a significant 
difference in hemoglobin levels at the end of 24 
months between the two groups (12.0 ± 1.7 g/dl 
vs. 13.9 ± 1.7 g/dl, p<0.05).
While the change in LVID index and IVST index 
remained insignificant in group-A, PWT index 
(from 4.8 ± 1.1 mm / m2 to 6.0 ± 0.9 mm / m2, P 
= 0.009) increased significantly after two years 
(Table III). As a result, LVMI increased 
significantly from 90 ± 21 g / m2 to 107 ± 26 g / 
m2 in group A (p=0.041). LVID index, IVST index, 
PWT index did not change in group B. Therefore, 
LVMI did not change in group B (113 ± 34 g / m2 
vs 112 ± 29 g / m2) after two years.
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T a b le  I: Clinical characteristics and biochemistry of controlled HT (A) and uncontrolled HT (B) groups of renal transplant 
recipients at baseline and after 24 months.
Group A (n = 14) Group B (n = 10)
Baseline 24th month Baseline 24th month
Age (years) 36 ±9 35 ±9
Gender (male / female, n) 8/6 8/2
Duration of dialysis before Tx (mo) 20 ±20 24 ±22
Duration of renal Tx (mo) 47 ±27 55 ± 31
Serum creatinine (mg / dl) 1.32 ±0.31 1.51 ±0.47" 1.25 ±0.33 1.34 ±0.39
Hemoglobin (g / dl) 12.6 ±2.0 12.0 ±1.7 13.5 ±1.3 13.9 ± 1.7t
Blood cyclosporine-A level (ng / ml) 159 ±39 163 ±38 157 ±25 147 ±31
Values are expressed as mean ± SO -p< 0.05 vs baseline in group A, tp<0.05 vs group A at 24th month. 
Tx: transplantation.
T a b le  II: ABPM and antihypertensive drug data of controlled HT (A) and uncontrolled HT (B) groups of renal transplant 
recipients at baseline and after 24 months.
Group A (n = 14) Group B (n = 10)
Baseline 24lh month Baseline 24lh month
Uncontrolled HT (%) 0 0 100 30
24-hour SBP (mm Hg) 118 ± 7 118 ± 8 143 ±12* 126 ± 8t*
24-hour DBP (mm Hg) 78 ±5 77 ±4 88 ±6* 77 ± 8t
Daytime SBP (mm Hg) 121 ±8 122 ±7 143 ± 11* 128 ± 7t
Daytime DBP (mm Hg) 80 ±5 79 ±4 89 ± 4§ 80 ± 7t
Nighttime SBP (mm Hg) 112 ± 8 114 ± 10 144 ± 20* 121 ±12t
Nighttime DBP (mm Hg) 72 ±4 74 ±6 86 ± 11 § 72 ± 10+
Antihypertensive drugs (n) 1.5 ±0.8 1.5 ±0.8 1.6 ±0.8 2.6 ± 0.8«
•ACEI 4/14 4/14 1/10 8/1Ott
• Calcium channel blockers 14/14 14/14 10/10 10/10
• a- receptor blockers 2/14 2/14 2/10 5/10*
• ß-receptor blockers 1/14 1/14 2/10 2/10
• Diuretic 0/14 0/14 0/10 0/10
• Others 0/14 0/14 1/10 1/10
Values are expressed as mean ± SD
'p<0.001 vs group A at baseline, tp<0.01 vs baseline, *p<0.05 vs group A at 24lh month, §p<0.005 vs group A at baseline, 
sp<0.0001 vs baseline, Hp<0.01 vs group A at 24,h month,
ABPM: Ambulatory blood pressure monitorization; SBP; Systolic blood pressure; DBP: Diastolic blood pressure,
ACEI: Angiotensin converting enzyme inhibitor.
T a b le  III: Echocardiography of Controlled HT (A) and uncontrolled HT (B) groups of renal transplant recipients at baseline and 
after 24 months.
Group A (n = 14) Group B (n = 10)
Baseline 24,h month Baseline 24th month
LVID index (mm / m2) 28.5 ±3.2 27.6 ± 3.3 26.3 ± 3.2 25.7 ±3.3
IVST index (mm / m2) 5.3 ±1.2 5,9 ±0.6 6.4 ± 0.9* 6.0 ± 0.6
PWT index (mm / m2) 4.8 ±1.0 6.0 ± 0.9* 5.7 ± 1.0* 5.9 ±1.1
LVMI (g / m2) 90 ±21 107 ±26H 113 ±34 112 ±29
Values are expressed as mean ± SD
‘p=0.01 vs group A at baseline, tp=0.009 vs baseline, *p<0.05 vs group A at baseline, Hp<0.05 vs baseline. 
LVID: Left ventricular internal diameter; IVST: Interventricular septal thickness; PWT: Posterior wall thickness.
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DISCUSSION
This study demonstrated that better control of HT 
did not result in regression of LVMI in long term 
renal transplant recipients with "uncontrolled-HT" 
(group B) and maintenance of BP control in the 
group with "controlled-HT" (group A) did not 
prevent progression of LVMI after 24 months of 
follow-up.
Previous studies demonstrated that control of HT 
resulted in improvement of LVMI LVH in renal 
transplant recipients in the early posttransplant 
period (8,9). Rigatto et al. reported that 
regression of LVMI was an ongoing process 
during the first 2 years of transplantation and 
reached a nadir in the third and fourth 
posttranplant years (10). In contrast to this study, 
de Lima et al. reported that LVMI continued to 
regress from 172 g/m2 to 136 g/m2 during 40 
months of follow-up (16). However, in this study, 
first echocardiography was performed 12 months 
after renal transplantation, and the second 
echocardiography was performed almost 2 years 
after the first one. This study was quite similar to 
design of our study in that they also included 
patients with duration of transplantation more 
than 12 months. However, in our study, we 
intended to control HT in the recipients with 
uncontrolled HT and maintain controlled BP in 
the recipients with controlled HT. ABPM were 
done for all recipients at baseline and at the end 
of 2 years to determine the level of control of HT. 
ABPM is accepted as the method more closely 
associated with LVMI compared to clinical 
measurements following renal transplantation 
(17, 18).
The increase in LVMI in our renal transplant 
recipients with controlled HT at baseline was due 
to increase in the wall thickness of left ventricle. 
Our findings indicate that control of HT may be a 
weak factor to influence the course of LVMI in 
long term renal transplant recipients. The 
progression in LVMI in this group was probably 
secondary to significant worsening of renal 
function and anemia. However, increased use of 
ACEI and preservation of renal function and 
hemoglobin level may be responsible from the 
maintenance of LVMI In patients with 
“uncontrolled HT". In our study, the decrease in 
hemoglobin values in group A might explain the 
increment in LVMI in group A (19).
In this study, we used ABPM measurement for all 
recipients at baseline and at the end of 2 years. 
ABPM is accepted as the method more closely 
associated with LVMI compared to clinical 
measurements following renal transplantation
(17).
A major limitation in this study is that, groups 
were small to reach a sufficient power to evaluate 
independent effects of other factors such as 
decrease in renal function and anemia and the 
use of ACEI on the structure of left ventricle at 
long term.
In conclusion, control of HT did not result in 
regression of LVMI in long term renal transplant 
recipients. Worsening of renal function and 
anemia are probably more important risk factors 
for the maintanence of LVH at long term in renal 
transplant recipients. Increased use of ACEI 
would probably effect the left ventricular structure 
in those patients. Long-term follow-up studies in 
a large cohort of renal transplant population 
should be performed in order to investigate 
whether control of these factors and increased 
use of ACEI could lead to regression of LVH and 
have a beneficial effects on cardiovascular 
outcome.
REFERENCES
1. Lind holm  A, A lbrechtsen D, Frodin L, 
Tufveson G, Persson TUI, Lundgren G. 
Ischemic heart disease-m ajor cause o f death 
and graft loss after renal transplantation in 
Scandinavia. Transplantation 1995; 60: 451- 
457.
2. Rigatto C, Farfrey P, Foiey R, Tiegrijn C, Tribula 
C, Jeffery J. Congestive heart failure in renal 
transplant recipients: risk factors, outcomes, 
and relationship with ischemic heart disease. 
J  Am Soc Hephrol 20 0 2 ; 13: 1084-1090.
3. Silberberg JS, Barre PE, Prichard SS, 
Snidermann AD. Im pact o f left ventricular 
hypertrophy on survival o f end-stage renal 
disease. Kidney Int 1989 ; 36: 286-290.
4. McGregor E, Jardine AG, Murray LS, et al. Pre­
operative échocardiographie abnorm alities  
and adverse outcom e following renal 
transplantation. Mephrol D ial Transplant 
1998; 13: 1499-1505.
5. McGregor E, Stewart G, Rodger RS, Jardine
AG. Early échocardiographie changes and
177
Mehmet Koç, et al.
survival following renal transplantation. 
Hephrol Dial Transplant 2 0 0 0 ; 15: 95-98.
6. Foley RH, Farfrey FS, Harnett JD, Kent OF1, 
Murray DC, Barre FE. Im pact o f hypertension 
on cardiomyopathy, m orbidity and mortality 
in end stage renal disease. Kidney Int 1996; 
49: 1379-1385.
7. Huting J. Course o f  left ventricular 
hypertrophy and function in end-stage renal 
disease after renal transplantation. Am J  
Cardiol 1992; 70: 1481-1484.
8. Farfrey FS, Harnett JD, Foley RH, et al. Impact 
o f  renal transplantation on urem ic  
cardiomyopathy. Transplantation 1995; 60: 
908-914 .
9. Midtvedt K, Ihlen H, Hartmann A, et al.
Reduction o f left ventricular mass by lisinopril 
and n ifed ip ine in hypertensive renal 
transplant recipients: a prospective
random ised double-blind  study.
Transplantation 2 0 0 1 ; 72: 107-111.
10. Rigatto C, Foley RH, Kent QM, Quttmann R, 
Farfrey FS. Long-term changes in left 
ventricular hypertrophy a fte r renal 
transplantation. Transplantation 2 0 0 0 ; 70: 
570-575 .
1 1 .  Koc M, Toprak A, O zener IC, et al. QT  
dispersion in renal transplant recipients. 
Hephron 20 0 2 ; 91: 250 -254 .
12. The Sixth Report o f  the Jo in t national 
C om m ittee on Prevention, Detection, 
Evaluation and Treatm ent o f  High Blood 
Fressure. Arch o f Int Med, 1997; 157: 2413 - 
2448.
13. Burt VL, Cutler JA, Higgins M,, et al. Trends in 
the prevalence, awareness, treatment, and  
control o f  hypertension in the adult US 
population. Data from the health examination  
surveys, I9 6 0  to 1991. Hypertension 1995; 
26: 60-69.
14. Sahn DJ, DeMaria A, Kisslo J, Weyman A. 
Recommendations regarding quantitation in 
M-mode echocardiography: results o f a survey 
o f échocardiographie m easurem ents. 
Circulation 1978; 58: 1072-1083.
15. Devereux RB, Alonso DR, Lutas EM, et al.
Echocardiographie assessm ent o f  left 
ventricular hypertrophy: com parison to
necropsy findings. Am J  Cardiol 1986; 57: 
450-458.
16. De Lima JJ, Vieira ML, Viviani LF, et al. Long­
term  im pact o f  renal transplantation on 
carotid artery properties and on ventricular 
hypertrophy in end-stage renal fa ilure  
patients. Hephrol Dial Transplant 2002 : 17: 
645-651.
I 7. Fernandez-Vega F, Tejada F, Baltar J, Laures 
A, Oomez E, Alvarez J. A m bulatoiy blood  
pressure after renal transplantation. Hephrol 
Dial Transplant 2001  ; 16 (Suppl I): 110-113.
18. Toprak A, Koc M, Tezcan H, O zener 1C, Oktay 
A, Akoglu E. Highttime blood pressure load is 
associated with higher left ventricular mass 
index in renal transplant recipients. J  Hum  
Hypertens 2 0 0 3 ; I 7: 239 -244 .
19. Foley RH, Farfrey FS, Kent QM, tlarnett JD, 
Murray DC, Barre FE. Long-term evolution o f  
cardiomyopathy in dialysis patients. Kidney 
Int 1998: 54: ¡7 2 0 -1 7 2 5 .
178
